Anheuser-Busch InBev tops estimates in last quarter where Bud Light boycott hits growth
By Steve Goldstein
Anheuser-Busch InBev reported stronger-than-forecast first-quarter profits in what was the final period where the consumer boycott of Bud Light will impact growth.
Anheuser-Busch InBev said its first-quarter profit slumped to $1.09 billion from $1.64 billion, while revenue rose 2.6% to $14.55 billion.
What it calls underlying earnings per share rose to 75 cents a share from 65 cents a share.
Analysts polled by Visible Alpha expected operating earnings of 62 cents a share on revenue of $14.4 billion.
The company's Brussels-listed shares (BE:ABI) (BUD) rose 5% in early action. They've gained 5% over the last 52 weeks.
Organic volume fell 0.6%, as a nearly 10% decline in North America was mostly offset by gains elsewhere, notably in Europe, Mexico and Colombia.
Sales in the U.S. have tumbled since transgender star Dylan Mulvaney made a social-media post about a personalized can of Bud Light, triggering anger as well as confusion from its customers.
In the U.S. in particular, EBITDA fell by 17.9% on a 9.1% decline in revenue.
Mulvaney's social-media post promoting Bud Light was made on April 1, 2023, meaning that the company's future performance will be compared to the period after the boycotts began.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-08-24 0344ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks